Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Goodwill (2016 - 2025)

Ligand Pharmaceuticals' Goodwill history spans 15 years, with the latest figure at $101.5 million for Q3 2025.

  • For Q3 2025, Goodwill fell 3.52% year-over-year to $101.5 million; the TTM value through Sep 2025 reached $101.5 million, down 3.52%, while the annual FY2024 figure was $105.2 million, 2737.69% up from the prior year.
  • Goodwill for Q3 2025 was $101.5 million at Ligand Pharmaceuticals, roughly flat from $101.5 million in the prior quarter.
  • Across five years, Goodwill topped out at $181.2 million in Q2 2022 and bottomed at $3.7 million in Q3 2023.
  • The 4-year median for Goodwill is $105.2 million (2024), against an average of $94.1 million.
  • The largest annual shift saw Goodwill plummeted 96.49% in 2023 before it surged 2737.69% in 2024.
  • A 4-year view of Goodwill shows it stood at $105.7 million in 2022, then tumbled by 96.49% to $3.7 million in 2023, then soared by 2737.69% to $105.2 million in 2024, then dropped by 3.52% to $101.5 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's Goodwill are $101.5 million (Q3 2025), $101.5 million (Q2 2025), and $105.2 million (Q4 2024).